Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jun 8;35(10):109226.
doi: 10.1016/j.celrep.2021.109226.

Nucleocytoplasmic transport of the RNA-binding protein CELF2 regulates neural stem cell fates

Affiliations
Free article

Nucleocytoplasmic transport of the RNA-binding protein CELF2 regulates neural stem cell fates

Melissa J MacPherson et al. Cell Rep. .
Free article

Abstract

The development of the cerebral cortex requires balanced expansion and differentiation of neural stem/progenitor cells (NPCs), which rely on precise regulation of gene expression. Because NPCs often exhibit transcriptional priming of cell-fate-determination genes, the ultimate output of these genes for fate decisions must be carefully controlled in a timely fashion at the post-transcriptional level, but how that is achieved is poorly understood. Here, we report that de novo missense variants in an RNA-binding protein CELF2 cause human cortical malformations and perturb NPC fate decisions in mice by disrupting CELF2 nucleocytoplasmic transport. In self-renewing NPCs, CELF2 resides in the cytoplasm, where it represses mRNAs encoding cell fate regulators and neurodevelopmental disorder-related factors. The translocation of CELF2 into the nucleus releases mRNA for translation and thereby triggers NPC differentiation. Our results reveal that CELF2 translocation between subcellular compartments orchestrates mRNA at the translational level to instruct cell fates in cortical development.

Keywords: CELF2; RNA-binding proteins; cell fate decision; cortical development; neural stem cells; neurodevelopmental disorder; neurogenesis; nucleocytoplasmic translocation; rare disease; translational repression.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests M.M. is employed by Blueprint Genetics. L.M. has received personal fees from Mendelian Ltd outside the submitted work. The other authors declare no competing interests.

Publication types

MeSH terms

Grants and funding